Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca (LON:AZN) in a report published on Wednesday morning, Borsen Zeitung reports. The firm currently has a sell rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently weighed in on AZN. Morgan Stanley upped their price target on SYSCO from $69.00 to $72.00 and gave the stock an equal weight rating in a report on Tuesday, May 7th. Liberum Capital restated a sell rating on shares of Pendragon in a report on Thursday, June 27th. UBS Group upgraded to a neutral rating and increased their target price for the company from GBX 945 ($12.35) to GBX 2,060 ($26.92) in a report on Thursday, June 20th. Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Finally, Kepler Capital Markets set a €11.00 ($12.79) target price on E.On and gave the company a buy rating in a report on Monday, May 13th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of GBX 6,502.94 ($84.97).
AZN opened at GBX 6,324 ($82.63) on Wednesday. The firm has a market cap of $82.96 billion and a PE ratio of 33.28. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The stock has a 50 day moving average price of GBX 6,247.96. AstraZeneca has a 1-year low of GBX 5,240 ($68.47) and a 1-year high of GBX 6,634 ($86.68).
In other AstraZeneca news, insider Philip A. J. Broadley acquired 520 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were acquired at an average price of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Blue-Chip Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.